Pleiotropic activity of lysophosphatidic acid in bone metastasis

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1831, Issue 1, 2013, Pages 99-104

  Peyruchaud, Olivier ^a   Leblanc, Raphael ^b   David, Marion ^b  

^a CNRS   (France)

^b UNIVERSITÉ LYON 1   (France)

Author keywords

Autotaxin; Bone metastasis; Lysophosphatidic acid; Mouse model; Osteoblast; Osteoclast

Indexed keywords

AUTOTAXIN; LYSOPHOSPHATIDIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; BONE METASTASIS; BONE PAIN; CANCER CELL; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOLYSIS; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; THROMBOCYTE;

ANIMALS; BONE NEOPLASMS; GENETIC PLEIOTROPY; HUMANS; LYSOPHOSPHOLIPIDS; OSTEOBLASTS; PAIN; PHOSPHORIC DIESTER HYDROLASES;

ANIMALIA;

EID: 84868574394     PISSN: 13881981     EISSN: 18792618     Source Type: Journal    
DOI: 10.1016/j.bbalip.2012.06.004     Document Type: Review

References (80)

1. R.E. Coleman Skeletal complications of malignancy Cancer 80 1997 1588 1594
2. R. Coleman The use of bisphosphonates in cancer treatment Ann. N. Y. Acad. Sci. 1218 2011 3 14
3. S. Harada, and G.A. Rodan Control of osteoblast function and regulation of bone mass Nature 423 2003 349 355
4. C.R. Jacobs, S. Temiyasathit, and A.B. Castillo Osteocyte mechanobiology and pericellular mechanics Annu. Rev. Biomed. Eng. 12 2010 369 400
5. T.A. Guise, J.J. Yin, S.D. Taylor, Y. Kumagai, M. Dallas, B.F. Boyce, T. Yoneda, and G.R. Mundy Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis J. Clin. Invest. 98 1996 1544 1549
6. K.N. Weilbaecher, T.A. Guise, and L.K. McCauley Cancer to bone: a fatal attraction Nat. Rev. Cancer 11 2011 411 425
7. T.A. Guise, J.J. Yin, and K.S. Mohammad Role of endothelin-1 in osteoblastic bone metastases Cancer 97 2003 779 784
8. R.E. Coleman, H. Marshall, D. Cameron, D. Dodwell, R. Burkinshaw, M. Keane, M. Gil, S.J. Houston, R.J. Grieve, P.J. Barrett-Lee, D. Ritchie, J. Pugh, C. Gaunt, U. Rea, J. Peterson, C. Davies, V. Hiley, W. Gregory, R. Bell, and A. Investigators Breast-cancer adjuvant therapy with zoledronic acid N. Engl. J. Med. 365 2011 1396 1405
9. M.R. Smith, F. Saad, R. Coleman, N. Shore, K. Fizazi, B. Tombal, K. Miller, P. Sieber, L. Karsh, R. Damiao, T.L. Tammela, B. Egerdie, H. Van Poppel, J. Chin, J. Morote, F. Gomez-Veiga, T. Borkowski, Z. Ye, A. Kupic, R. Dansey, and C. Goessl Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial Lancet 379 2012 39 46
10. W.H. Moolenaar Development of our current understanding of bioactive lysophospholipids Ann. N. Y. Acad. Sci. 905 2000 1 10
11. M. David, E. Wannecq, F. Descotes, S. Jansen, B. Deux, J. Ribeiro, C.M. Serre, S. Gres, N. Bendriss-Vermare, M. Bollen, S. Saez, J. Aoki, J.S. Saulnier-Blache, P. Clezardin, and O. Peyruchaud Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts PLoS One 5 2010 e9741
12. L.M. Masiello, J.S. Fotos, D.S. Galileo, and N.J. Karin Lysophosphatidic acid induces chemotaxis in MC3T3-E1 osteoblastic cells Bone 39 2006 72 82
13. S.A. Karagiosis, and N.J. Karin Lysophosphatidic acid induces osteocyte dendrite outgrowth Biochem. Biophys. Res. Commun. 357 2007 194 199
14. O. Peyruchaud, B. Winding, I. Pecheur, C.M. Serre, P. Delmas, and P. Clezardin Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions J. Bone Miner. Res. 16 2001 2027 2034
15. A. Boucharaba, C.-M. Serre, S. Gres, J.S. Saulnier-Blache, J.-C. Bordet, J. Guglielmi, P. Clezardin, and O. Peyruchaud Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer J. Clin. Invest. 114 2004 1714 1725
16. A. Boucharaba, C.M. Serre, J. Guglielmi, J.C. Bordet, P. Clezardin, and O. Peyruchaud The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases Proc. Natl. Acad. Sci. U. S. A. 103 2006 9643 9648
17. H. Ohta, K. Sato, N. Murata, A. Damirin, E. Malchinkhuu, J. Kon, T. Kimura, M. Tobo, Y. Yamazaki, T. Watanabe, M. Yagi, M. Sato, R. Suzuki, H. Murooka, T. Sakai, T. Nishitoba, D.S. Im, H. Nochi, K. Tamoto, H. Tomura, and F. Okajima Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors Mol. Pharmacol. 64 2003 994 1005
18. J.S. Swaney, C. Chapman, L.D. Correa, K.J. Stebbins, A.R. Broadhead, G. Bain, A.M. Santini, J. Darlington, C.D. King, C.S. Baccei, C. Lee, T.A. Parr, J.R. Roppe, T.J. Seiders, J. Ziff, P. Prasit, J.H. Hutchinson, J.F. Evans, and D.S. Lorrain Pharmacokinetic and pharmacodynamic characterization of an oral lysophosphatidic acid type 1 receptor-selective antagonist J. Pharmacol. Exp. Ther. 336 2011 693 700
19. J.S. Swaney, C. Chapman, L.D. Correa, K.J. Stebbins, R.A. Bundey, P.C. Prodanovich, P. Fagan, C.S. Baccei, A.M. Santini, J.H. Hutchinson, T.J. Seiders, T.A. Parr, P. Prasit, J.F. Evans, and D.S. Lorrain A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model Br. J. Pharmacol. 160 2010 1699 1713
20. T. Eichholtz, K. Jalink, I. Fahrenfort, and W.H. Moolenaar The bioactive phospholipid lysophosphatidic acid is released from activated platelets Biochem. J. 291 1993 677 680
21. J. Aoki, A. Taira, Y. Takanezawa, Y. Kishi, K. Hama, T. Kishimoto, K. Mizuno, K. Saku, R. Taguchi, and H. Arai Serum lysophosphatidic acid is produced through diverse phospholipase pathways J. Biol. Chem. 277 2002 48737 48744
22. L.A. van Meeteren, P. Ruurs, C. Stortelers, P. Bouwman, M.A. van Rooijen, J.P. Pradere, T.R. Pettit, M.J. Wakelam, J.S. Saulnier-Blache, C.L. Mummery, W.H. Moolenaar, and J. Jonkers Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development Mol. Cell. Biol. 26 2006 5015 5022
23. P. Cui, J.L. Tomsig, W.F. McCalmont, S. Lee, C.J. Becker, K.R. Lynch, and T.L. Macdonald Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors Bioorg. Med. Chem. Lett. 17 2007 1634 1640
24. L.M. Yuelling, and B. Fuss Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties Biochim. Biophys. Acta 1781 2008 525 530
25. R.L. van Bezooijen, B.A. Roelen, A. Visser, L. van der Wee-Pals, E. de Wilt, M. Karperien, H. Hamersma, S.E. Papapoulos, P. ten Dijke, and C.W. Lowik Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist J. Exp. Med. 199 2004 805 814
26. M. Umezu-Goto, Y. Kishi, A. Taira, K. Hama, N. Dohmae, K. Takio, T. Yamori, G.B. Mills, K. Inoue, J. Aoki, and H. Arai Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production J. Cell Biol. 158 2002 227 233
27. K. Hama, J. Aoki, M. Fukaya, Y. Kishi, T. Sakai, R. Suzuki, H. Ohta, T. Yamori, M. Watanabe, J. Chun, and H. Arai Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1 J. Biol. Chem. 279 2004 17634 17639
28. C.C. Chua, R.C. Hamdy, and B.H. Chua Upregulation of endothelin-1 production by lysophosphatidic acid in rat aortic endothelial cells Biochim. Biophys. Acta 1405 1998 29 34
29. J.J. Yin, K.S. Mohammad, S.M. Kakonen, S. Harris, J.R. Wu-Wong, J.L. Wessale, R.J. Padley, I.R. Garrett, J.M. Chirgwin, and T.A. Guise A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases Proc. Natl. Acad. Sci. U. S. A. 100 2003 10954 10959
30. Y. Daaka Mitogenic action of LPA in prostate Biochim. Biophys. Acta 1582 2002 265 269
31. Y. Xie, T.C. Gibbs, Y.V. Mukhin, and K.E. Meier Role for 18:1 lysophosphatidic acid as an autocrine mediator in prostate cancer cells J. Biol. Chem. 277 2002 32516 32526
32. D.S. Im, C.E. Heise, M.A. Harding, S.R. George, B.F. O'Dowd, D. Theodorescu, and K.R. Lynch Molecular cloning and characterization of a lysophosphatidic acid receptor, Edg-7, expressed in prostate Mol. Pharmacol. 57 2000 753 759
33. Y. Zeng, Y. Kakehi, M.A. Nouh, H. Tsunemori, M. Sugimoto, and X.X. Wu Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia Prostate 69 2009 283 292
34. Y. Li, and F.H. Sarkar Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein Cancer Lett. 186 2002 157 164
35. J.E. Damber, and G. Aus Prostate cancer Lancet 371 2008 1710 1721
36. R. Guo, E.A. Kasbohm, P. Arora, C.J. Sample, B. Baban, N. Sud, P. Sivashanmugam, N.H. Moniri, and Y. Daaka Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells Endocrinology 147 2006 4883 4892
37. P. Sivashanmugam, L. Tang, and Y. Daaka Interleukin 6 mediates the lysophosphatidic acid-regulated cross-talk between stromal and epithelial prostate cancer cells J. Biol. Chem. 279 2004 21154 21159
38. A. Grey, Q. Chen, K. Callon, X. Xu, I.R. Reid, and J. Cornish The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving G(i) proteins and phosphatidylinositol-3 kinase Endocrinology 143 2002 4755 4763
39. J. Gidley, S. Openshaw, E.T. Pring, S. Sale, and J.P. Mansell Lysophosphatidic acid cooperates with 1alpha,25(OH)2D3 in stimulating human MG63 osteoblast maturation Prostaglandins Other Lipid Mediat. 80 2006 46 61
40. J.P. Mansell, M. Nowghani, M. Pabbruwe, I.C. Paterson, A.J. Smith, and A.W. Blom Lysophosphatidic acid and calcitriol co-operate to promote human osteoblastogenesis: requirement of albumin-bound LPA Prostaglandins Other Lipid Mediat. 95 2011 45 52
41. Y.B. Liu, Y. Kharode, P.V. Bodine, P.J. Yaworsky, J.A. Robinson, and J. Billiard LPA induces osteoblast differentiation through interplay of two receptors: LPA1 and LPA4 J. Cell. Biochem. 109 2010 794 800
42. X. Ye, K. Hama, J.J. Contos, B. Anliker, A. Inoue, M.K. Skinner, H. Suzuki, T. Amano, G. Kennedy, H. Arai, J. Aoki, and J. Chun LPA3-mediated lysophosphatidic acid signalling in embryo implantation and spacing Nature 435 2005 104 108
43. I. Gennero, S. Laurencin-Dalicieux, F. Conte-Auriol, F. Briand-Mesange, D. Laurencin, J. Rue, N. Beton, N. Malet, M. Mus, A. Tokumura, P. Bourin, L. Vico, G. Brunel, R.O. Oreffo, J. Chun, and J.P. Salles Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass Bone 49 2011 395 403
44. J.J. Contos, I. Ishii, N. Fukushima, M.A. Kingsbury, X. Ye, S. Kawamura, J.H. Brown, and J. Chun Characterization of lpa(2) Edg4) and lpa(1)/lpa(2) (Edg2/Edg4) lysophosphatidic acid receptor knockout mice: signaling deficits without obvious phenotypic abnormality attributable to lpa(2 Mol. Cell. Biol. 22 2002 6921 6929
45. H. Sumida, K. Noguchi, Y. Kihara, M. Abe, K. Yanagida, F. Hamano, S. Sato, K. Tamaki, Y. Morishita, M.R. Kano, C. Iwata, K. Miyazono, K. Sakimura, T. Shimizu, and S. Ishii LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis Blood 116 2010 5060 5070
46. M.A. Nouh, X.X. Wu, H. Okazoe, H. Tsunemori, R. Haba, A.M. Abou-Zeid, M.D. Saleem, M. Inui, M. Sugimoto, J. Aoki, and Y. Kakehi Expression of autotaxin and acylglycerol kinase in prostate cancer: association with cancer development and progression Cancer Sci. 2009
47. G.J. Gasic, T.B. Gasic, N. Galanti, T. Johnson, and S. Murphy Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease Int. J. Cancer 11 1973 704 718
48. G.F. Nash, L.F. Turner, M.F. Scully, and A.K. Kakkar Platelets and cancer Lancet Oncol. 3 2002 425 430
49. J.M. Gerrard, and P. Robinson Identification of the molecular species of lysophosphatidic acid produced when platelets are stimulated by thrombin Biochim. Biophys. Acta 1001 1989 282 285
50. G.P. Gupta, and J. Massague Platelets and metastasis revisited: a novel fatty link J. Clin. Invest. 114 2004 1691 1693
51. M. Torti, E. Tolnai Festetics, A. Bertoni, F. Sinigaglia, and C. Balduini Activation of human platelets by lysophosphatidic acid Blood Coagul. Fibrinolysis 7 1996 253 255
52. A. Tokumura, K. Fukuzawa, J. Isobe, and H. Tsukatani Lysophosphatidic acid-induced aggregation of human and feline platelets: structure-activity relationship Biochem. Biophys. Res. Commun. 99 1981 391 398
53. Z. Pamuklar, J.S. Lee, H.Y. Cheng, M. Panchatcharam, S. Steinhubl, A.J. Morris, R. Charnigo, and S.S. Smyth Individual heterogeneity in platelet response to lysophosphatidic acid: evidence for a novel inhibitory pathway Arterioscler. Thromb. Vasc. Biol. 28 2008 555 561
54. Z. Pamuklar, L. Federico, S. Liu, M. Umezu-Goto, A. Dong, M. Panchatcharam, Z. Fulerson, E. Berdyshev, V. Natarajan, X. Fang, L.A. van Meeteren, W.H. Moolenaar, G.B. Mills, A.J. Morris, and S.S. Smyth Autotaxin/lysopholipase D and lysophosphatidic acid regulate murine hemostasis and thrombosis J. Biol. Chem. 284 2009 7385 7394
55. Z. Fulkerson, T. Wu, M. Sunkara, C.V. Kooi, A.J. Morris, and S.S. Smyth Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells J. Biol. Chem. 286 2011 34654 34663
56. N. Panupinthu, J.T. Rogers, L. Zhao, L.P. Solano-Flores, F. Possmayer, S.M. Sims, and S.J. Dixon P2X7 receptors on osteoblasts couple to production of lysophosphatidic acid: a signaling axis promoting osteogenesis J. Cell Biol. 181 2008 859 871
57. T. Yoneda, K. Hata, M. Nakanishi, M. Nagae, T. Nagayama, H. Wakabayashi, T. Nishisho, T. Sakurai, and T. Hiraga Involvement of acidic microenvironment in the pathophysiology of cancer-associated bone pain Bone 48 2011 100 105
58. M.E. Lin, D.R. Herr, and J. Chun Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance Prostaglandins Other Lipid Mediat. 91 2010 130 138
59. J. Zhao, H.L. Pan, T.T. Li, Y.Q. Zhang, J.Y. Wei, and Z.Q. Zhao The sensitization of peripheral C-fibers to lysophosphatidic acid in bone cancer pain Life Sci. 2010
60. H.L. Pan, Y.Q. Zhang, and Z.Q. Zhao Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKCepsilon pathway in dorsal root ganglion neurons Mol. Pain 6 2010 85
61. K. Pantel, C. Alix-Panabieres, and S. Riethdorf Cancer micrometastases Nat. Rev. Clin. Oncol. 6 2009 339 351
62. J.S. Ross, and E.A. Slodkowska Circulating and disseminated tumor cells in the management of breast cancer Am. J. Clin. Pathol. 132 2009 237 245
63. B. Psaila, and D. Lyden The metastatic niche: adapting the foreign soil Nat. Rev. Cancer 9 2009 285 293
64. K. Horiuchi, N. Amizuka, S. Takeshita, H. Takamatsu, M. Katsuura, H. Ozawa, Y. Toyama, L.F. Bonewald, and A. Kudo Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta J. Bone Miner. Res. 14 1999 1239 1249
65. K. Ruan, S. Bao, and G. Ouyang The multifaceted role of periostin in tumorigenesis Cell Mol. Life Sci. 66 2009 2219 2230
66. I. Malanchi, A. Santamaria-Martinez, E. Susanto, H. Peng, H.A. Lehr, J.F. Delaloye, and J. Huelsken Interactions between cancer stem cells and their niche govern metastatic colonization Nature 481 2012 85 89
67. S. Contie, N. Voorzanger-Rousselot, J. Litvin, P. Clezardin, and P. Garnero Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases Int. J. Cancer 2010
68. K.U. Choi, J.S. Yun, I.H. Lee, S.C. Heo, S.H. Shin, E.S. Jeon, Y.J. Choi, D.S. Suh, M.S. Yoon, and J.H. Kim Lysophosphatidic acid-induced expression of periostin in stromal cells: Prognoistic relevance of periostin expression in epithelial ovarian cancer Int. J. Cancer 2010
69. X. Lu, E. Mu, Y. Wei, S. Riethdorf, Q. Yang, M. Yuan, J. Yan, Y. Hua, B.J. Tiede, B.G. Haffty, K. Pantel, J. Massague, and Y. Kang VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors Cancer Cell 20 2011 701 714
70. H. Shimada, and L.E. Rajagopalan Rho kinase-2 activation in human endothelial cells drives lysophosphatidic acid-mediated expression of cell adhesion molecules via NF-kappaB p65 J. Biol. Chem. 285 2010 12536 12542
71. C. Rizza, N. Leitinger, J. Yue, D.J. Fischer, D.A. Wang, P.T. Shih, H. Lee, G. Tigyi, and J.A. Berliner Lysophosphatidic acid as a regulator of endothelial/leukocyte interaction Lab. Invest. 79 1999 1227 1235
72. K.R. Lynch, and T.L. Macdonald Structure-activity relationships of lysophosphatidic acid analogs Biochim. Biophys. Acta 1582 2002 289 294
73. G.B. Mills, and W.H. Moolenaar The emerging role of lysophosphatidic acid in cancer Nat. Rev. Cancer 3 2003 582 591
74. S. Liu, M. Umezu-Goto, M. Murph, Y. Lu, W. Liu, F. Zhang, S. Yu, L.C. Stephens, X. Cui, G. Murrow, K. Coombes, W. Muller, M.C. Hung, C.M. Perou, A.V. Lee, X. Fang, and G.B. Mills Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases Cancer Cell 15 2009 539 550
75. S. Yu, M.M. Murph, Y. Lu, S. Liu, H.S. Hall, J. Liu, C. Stephens, X. Fang, and G.B. Mills Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells J. Natl. Cancer Inst. 100 2008 1630 1642
76. Z. Lee, C.T. Cheng, H. Zhang, M.A. Subler, J. Wu, A. Mukherjee, J.J. Windle, C.K. Chen, and X. Fang Role of LPA4/p2y9/GPR23 in negative regulation of cell motility Mol. Biol Cell 2008
77. M. Jongsma, E. Matas-Rico, A. Rzadkowski, K. Jalink, and W.H. Moolenaar LPA is a chemorepellent for B16 melanoma cells: action through the cAMP-elevating LPA5 receptor PLoS One 6 2011 e29260
78. K. Bandoh, J. Aoki, A. Taira, M. Tsujimoto, H. Arai, and K. Inoue Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors FEBS Lett. 478 2000 159 165
79. Y. Fujiwara, V. Sardar, A. Tokumura, D. Baker, K. Murakami-Murofushi, A. Parrill, and G. Tigyi Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cells J. Biol. Chem. 280 2005 35038 35050
80. J. Gierse, A. Thorarensen, K. Beltey, E. Bradshaw-Pierce, L. Cortes-Burgos, T. Hall, A. Johnston, M. Murphy, O. Nemirovskiy, S. Ogawa, L. Pegg, M. Pelc, M. Prinsen, M. Schnute, J. Wendling, S. Wene, R. Weinberg, A. Wittwer, B. Zweifel, and J. Masferrer A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation J. Pharmacol. Exp. Ther. 334 2010 310 317